Close mobile menu×
Close mobile menu

Scott M. Hammer, MD

Board Certifications: 
Infectious Disease, Internal Medicine
Not Accepting New Patients

Appointments

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor

Board Certifications

  • Infectious Disease
  • Internal Medicine

Clinical Expertise

  • Infectious Diseases
  • HIV (Human Immunodeficiency Virus Infection)

Specialties

Education & Training

  • Columbia University College of Physicians and Surgeons
  • Internship: Columbia Presbyterian Medical Center, NY
  • Residency: Stanford University Medical Center
  • Residency: Columbia Presbyterian Medical Center, NY
  • Fellowship: Massachussetts General Hospital

About Scott Hammer

Dr. Hammer is the Harold C. Neu Professor of Medicine, Professor of Epidemiology and Chief of the Division of Infectious Diseases at the NewYork-Presbyterian/Columbia University Medical Center. Dr. Hammer’s major investigative interest is the treatment and prevention of HIV disease. He is an investigator in the National Institutes of Health sponsored AIDS Clinical Trials Group (ACTG), a multicenter organization which performs clinical trials designed to improve the understanding and treatment of HIV infection and its complications.

As an ACTG investigator, Dr. Hammer chaired the two largest national trials of antiretroviral therapy carried out by that group in the 1990’s, studies which contributed to the current standard of care of HIV infection. In addition to his interest in the treatment of persons with established HIV infection, Dr. Hammer is an investigator in the National Institutes of Health sponsored HIV Vaccine Trials Network (HVTN), a multicenter organization whose mission is to develop an effective preventive HIV vaccine. He is the current protocol chair of HVTN 505, a phase 2b test-of-concept efficacy study of the preventive HIV vaccine regimen developed by NIAID’s Vaccine Research Center. He is a former Chair of the AIDS Vaccine Research Working Group of the Division of AIDS, NIAID, and the Antiviral Products Advisory Committee of the Food and Drug Administration and currently serves on the Editorial Board of the New England Journal of Medicine.

Dr. Hammer has previously served as a member of the International AIDS Society’s Governing Council, Chair of the International AIDS Society-USA’s Antiretroviral Guidelines Panel and Vice Chair of the World Health Organization’s Strategic and Technical Advisory Committee for HIV/AIDS. He chaired the Guidelines Development Group of the WHO’s Antiretroviral Guidelines for Resource Limited Settings in 2002, 2003 and 2006 and co-chaired the Steering Committee of the WHO’s Global HIV Drug Resistance Surveillance Program. In his role as Chief of the Division of Infectious Diseases at NewYork-Presbyterian/Columbia, he is dedicated to optimizing care for patients with all forms of infectious diseases, fellow and faculty growth and to the development of state-of-the-art infection surveillance at the institutional and regional levels to improve and protect the public health.

Academic Titles

  • Harold C. Neu Professor of Infectious Diseases in the Department of Medicine
  • Professor of Epidemiology at CUMC

Administrative Positions

  • Chief, Division of Infectious Diseases

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Medicare

  • Traditional Medicare (NY)

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
180 Fort Washington Avenue
Suite 2-242
New York, New York 10032
Phone:
(212) 305-8039
Fax:
(212)-305-1754
Primary

Research

Dr. Hammer’s major investigative interest is the treatment and prevention of HIV disease. He is an investigator in the National Institutes of Health sponsored AIDS Clinical Trials Group (ACTG), a multicenter organization which performs clinical trials designed to improve the understanding and treatment of HIV infection and its complications.

As an ACTG investigator, Dr. Hammer chaired the two largest national trials of antiretroviral therapy carried out by that group in the 1990’s, studies which contributed to the current standard of care of HIV infection. In addition to his interest in the treatment of persons with established HIV infection, Dr. Hammer is an investigator in the National Institutes of Health sponsored HIV Vaccine Trials Network (HVTN), a multicenter organization whose mission is to develop an effective preventive HIV vaccine.
 
He is the current protocol chair of HVTN 505, an advanced phase II study of the preventive HIV vaccine regimen developed by NIAID’s Vaccine Research Center. He is a former Chair of the AIDS Vaccine Research Working Group of the Division of AIDS, NIAID, and the Antiviral Products Advisory Committee of the Food and Drug Administration and currently serves on the Editorial Board of the New England Journal of Medicine.
 
Dr. Hammer is a former Chair of the International AIDS Society-USA’s Antiretroviral Guidelines Panel and former Vice Chair of the World Health Organization’s Strategic and Technical Advisory Committee for HIV/AIDS. He chaired the Guidelines Development Group of the WHO’s Antiretroviral Guidelines for Resource Limited Settings in 2002, 2003 and 2006 and co-chaired the Steering Committee of the WHO’s Global HIV Drug Resistance Surveillance Program. In his role as Chief of the Division of Infectious Diseases at CUMC, he is dedicated to fellow and faculty growth and to the development of state-of-the-art infection surveillance at the institutional and regional levels to improve and protect the public health.

Grants

COLUMBIA INTEGRATED TRAINING PROGRAM IN INFECTIOUS DISEASES RESEARCH (Federal Gov)

Jun 1 2013 - May 31 2023

COLUMBIA PARTNERSHIP FOR PREVENTION AND CONTROL OF HIV/AIDS CLINICAL TRIALS UNIT (COLUMBIA PARTNERSHIP CTU) (Federal Gov)

Dec 1 2013 - Nov 30 2020

HPTN 083 PROTOCOL FUNDING - DEVELOPMENT COST (Federal Gov)

May 1 2016 - Nov 30 2018

AIDS CLINICAL TRIALS GROUP (ACTG) (Federal Gov)

Jul 1 2016 - Nov 30 2016

HVTN 703/HPTN 081 - BRONX PEVENTION CENTER CRS (Federal Gov)

Aug 1 2015 - Nov 30 2016

HVTN 703/HPTN 081 - HARLEM PREVENTION CENTER CRS (Federal Gov)

Aug 1 2015 - Nov 30 2015

HPTN 076 PROTOCOL FUNDING (Federal Gov)

Jun 1 2014 - Nov 30 2014

HVTN SCIENTIFIC LEADERSHIP (HAMMER) (Federal Gov)

Jan 1 2014 - Nov 30 2014

THE IMPACT OF MOBILITY ON HIV CARE IN NEW YORK AND DOMINICAN REPUBLIC (Federal Gov)

Jul 1 2011 - Jun 30 2014

HVTN CLINICIAN (Federal Gov)

Jul 1 2005 - Jun 30 2014

HVTN 505CORE LEADERSHIP ROLE (Federal Gov)

Jun 1 2009 - Dec 31 2013

HVTN SCIENTIFIC LEADERSHIP (Federal Gov)

Jun 1 2009 - Dec 31 2013

ENHANCING, TRAINING, RESEARCH CAPACITY AND EXPERTISE IN HIV CARE-ENTREE MEDICAL EDUCATION PARTNERSHIP INITIATIVE (Federal Gov)

Sep 27 2010 - Aug 31 2013

HIV VACCINE TRIALS UNIT - HVTN 505 (Federal Gov)

Jun 1 2009 - Aug 31 2013

NEW YORK (COLUMBIA UNIVERSITY) USA HIV VACCINE TRIALS UNIT - PIF FUNDING (Federal Gov)

Jun 1 2008 - Aug 31 2013

SAN FRANCISCO VACCINE AND PREVENTION UNIT (Federal Gov)

Apr 1 2013 - Jun 30 2013

THE IMPACT OF MOBILITY ON HIV CARE IN NEW YORK AND THE DOMIN ICAN REPUBLIC (Federal Gov)

Jul 1 2011 - Jun 30 2013

THE IMPACT OF MOBILITY ON HIV CARE IN NEW YORK AND THE DOMIN ICAN REPUBLIC (Federal Gov)

Jul 1 2011 - Jun 30 2013

HIV VACCINE TRIALS UNIT - HVTN 505 (Federal Gov)

Jun 1 2009 - May 31 2013

HIV VACCINE TRIALS UNIT - HVTN 505 (Federal Gov)

Jun 1 2009 - May 31 2013

HVTN 505 CORE LEADERSHIP ROLE (Federal Gov)

Jun 1 2009 - May 31 2013

HVTN 505CORE LEADERSHIP ROLE (Federal Gov)

Jun 1 2009 - May 31 2013

HVTN SCIENTIFIC LEADERSHIP (Federal Gov)

Jun 1 2009 - May 31 2013

NEW YORK (COLUMBIA UNIVERSITY) USA HIV VACCINE TRIALS UNIT - PIF FUNDING (Federal Gov)

Jun 1 2008 - May 31 2013

PREVENTION UMBRELLA FOR MSM IN THE AMERICAS (Federal Gov)

Sep 1 2012 - Mar 31 2013

THE IMPACT OF MOBILITY ON HIV OUTCOMES IN NEW YORK CITY AND THE DOMINICAN REPUBLIC (Private)

Jan 1 2010 - Dec 31 2012

ENHANCING, TRAINING, RESEARCH CAPACITY AND EXPERTISE IN HIV CARE-ENTREE MEDICAL EDUCATION PARTNERSHIP INITIATIVE (Federal Gov)

Sep 27 2010 - Aug 31 2012

KWAZULU-NATAL UNIVERSITY-COLUMBIA UNIVERSITY MENTORING AGREE MENT (Federal Gov)

Mar 1 2007 - Jan 31 2010

HIV VACCINE TRIALS UNIT - LEGACY PROJECT (Federal Gov)

Sep 1 2007 - May 31 2009

VIROLOGY SUPPORT LABORATORY (VSL) COOPERATIVE AGREEMENT (Federal Gov)

Jan 1 2000 - Dec 31 2004

Selected Publications

  • Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC (for the ACTG 175 study team). A trial of nucleoside monotherapy vs. combination therapy in HIV-infected adults with CD4 cell counts between 200 and 500 per cubic millimeter: NIAID-sponsored AIDS clinical trials group study 175. N Engl J Med. 1996;335:1081-1096.
  • Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA (for the AIDS clinical trials group 320 study team). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
  • Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 1: Cellular and humoral immune responses. Ann Intern Med. 2001;134:761-776.
  • Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: Genetic factors and implications for antiretroviral therapeutics. Ann Intern Med. 2001;134:978-996.
  • Hammer SM. Increasing choices for HIV therapy. N Engl J Med. 2002;346:2022-2023.
  • Hammer S, Gibb D, Havlir D, Mofenson L, VAn Beek I, Vella S, Vareldzis B, Perriens J and the WHO Writing Committee: Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. World Health Organization, April 2002, available at www.who.int.
  • Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, and Mellors JW (for the AIDS clinical trials group 398 study team). Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: A randomized trial. J Am Med Assoc. 2002;288:169-180.
  • Hammer SM, Bassett R, Squires KE, Fischl M, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, and DeGruttola V. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther. 2003;8:507-518.
  • Hammer SM, Mofenson L, Havlir D, Vitorio M, Perriens J and the WHO Writing Committee: Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 version. World Health Organization, December 2003, available at www.who.int.
  • Hammer SM. Clinical practice. Management of newly diagnosed HIV infection. N Engl J Med. 2005;353:1702-1710.
  • Sobieszczyk ME, Jones J, Wilkin T, Hammer SM. Advances in antiretroviral therapy. Top HIV Med. 2006;14:36-62.
  • Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM,
  • Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS,
  • Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. JAMA 2006;296:827-43.
  • Gripshover BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki
  • B, Hammer SM, Kuritzkes DR; A5118 Team. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006;11:619-23.
  • Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM,
  • Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS,
  • Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med. 2006;14:827-43.
  • Hammer S, Riley A, Calmy A, Harries A, Duncombe C, Havlir D, Katabira E, Scano F, Malkin JE, Lange J, Mukerjee J, Currier J, Mofenson L, Harrington M, Schechter M, Kumarasamy N, Sow PS, Munderi P, Ojoo S, Cahn P, Phanuphak P, Eholie S, El Sadr W, Rodriguez W: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2006 revision. World Health Organization, August 2006, available at www.who.int.
  • Taylor BS, Sobieszczyk ME, McCutchan FE and Hammer SM: The challenge of HIV-1 subtype diversity. NEJM 2008;358:1590-1602.
  • Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM and Richman DD: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society - USA Panel. Clin Infect Dis 2008;47:266-285
  • Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JSG, Richman DD, Yeni PG and Volberding PA: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society – USA Panel. JAMA 2008; 300:555-570.
  • Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S and Squires K: Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials 2008;9:11-25